AstraZeneca PLC (LON:AZN) Receives Consensus Rating of “Moderate Buy” from Analysts

Shares of AstraZeneca PLC (LON:AZN) have been given an average rating of “Moderate Buy” by the nine research firms that are presently covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and six have assigned a buy recommendation to the company. The average 12 month price target among brokerages that have issued ratings on the stock in the last year is GBX 7,935.67 ($97.65).

A number of equities research analysts have commented on AZN shares. JPMorgan Chase & Co. restated an “overweight” rating and issued a £140 ($172.27) price target on shares of AstraZeneca in a report on Friday, November 22nd. Berenberg Bank restated a “buy” rating and issued a GBX 140 ($1.72) target price on shares of AstraZeneca in a research note on Monday. Finally, Shore Capital reaffirmed a “buy” rating on shares of AstraZeneca in a research report on Thursday, November 7th.

Insider Transactions at AstraZeneca

In other AstraZeneca news, insider Tony Mok purchased 1,500 shares of the company’s stock in a transaction that occurred on Tuesday, November 19th. The shares were bought at an average cost of £126.80 ($156.02) per share, for a total transaction of £190,200 ($234,034.70). Also, insider Pascal Soriot acquired 20,000 shares of AstraZeneca stock in a transaction that occurred on Thursday, November 14th. The stock was acquired at an average price of £102.03 ($125.54) per share, with a total value of £2,040,600 ($2,510,889.63). 0.04% of the stock is currently owned by company insiders.

AstraZeneca Stock Performance

Shares of AZN stock opened at £109.88 ($135.20) on Friday. The firm has a 50 day moving average of £104.83 and a 200-day moving average of £116.65. The company has a market cap of £170.31 billion, a price-to-earnings ratio of 3,488.25, a price-to-earnings-growth ratio of 0.86 and a beta of 0.17. The company has a quick ratio of 0.59, a current ratio of 0.89 and a debt-to-equity ratio of 84.97. AstraZeneca has a 52 week low of GBX 9,461 ($116.41) and a 52 week high of £133.88 ($164.73).

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.